Journal of Immunology Research / 2020 / Article / Tab 1

Review Article

CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

Table 1

Drugs targeting CD47-SIRPα axis that are currently being tested in humans.

Drug nameCompanyMechanism of actionClinical trial IDTarget malignancyCombined withClinical phaseStatus (June 2020)

Magrolimab (Hu5F-G4)Gilead Sciences (previously, Forty-Seven Inc.)Anti-CD47 mAbNCT02953509Relapsing NHLRituximabPhase 1 & 2Recruiting
NCT03869190Urothelial carcinomaSeveralPhase 1 & 2Recruiting
NCT03248479AML & MDSAzacitidinePhase 1Recruiting

BI735063OSE Immunotherapeutics/Boehringer IngelheimAnti-SIRPα mAbNCT03990233Advanced solid tumorsMonotherapy or PD-1 inhibitor (BI 754091)Phase 1Recruiting

CC95251CelgeneAnti- SIRPα mAbNCT03783403Advanced solid & hematologic cancersRituximab or CetuximabPhase 1Recruiting

IBI188Innovent Biologics (Suzhou) Co. Ltd.Anti-CD47 mAbNCT03763149Advanced malignant tumors and lymphomasMonotherapyPhase 1Recruiting
NCT03717103Advanced malignanciesRituximabPhase 1Recruiting

TTI621Trillium Therapeutics Inc.SIRPαFc-soluble recombinant fusion proteinNCT02663518Hematologic malignancies and selected solid tumorsRituximab or NivolumabPhase 1Recruiting

TT622Trillium Therapeutics Inc.SIRPα-IgG4 Fc-soluble recombinant fusion proteinNCT03530683Refractory lymphoma and myelomaMonotherapy, rituximab, PD-1 inhibitor, or proteasome inhibitorPhase 1Recruiting

AO176Arch OncologyAnti-CD47 mAbNCT03834948Multiple solid malignanciesMonotherapyPhase 1Recruiting

ALX148ALX Oncology Inc.SIRPα soluble recombinant fusion proteinNCT03013218Advanced Solid & Hematologic CancersMonotherapy, Pembrolizumab, Trastuzumab, rituximab, Ramucirumab+ Paclitaxel, 5-FU+ CisplatinPhase 1Recruiting

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.